NeuroEPO clinical trial advances in Holguín
- Written by Redacción ¡ahora!
- Published in Holguin
- Hits: 872
The clinical trial (CE) with NeuroEPO or Neural CIM in patients with Alzheimer's, advances in the province of Holguín, as part of the programs to improve the treatments of this neurocognitive disease.
Dr. Zaimar Rodríguez Feria, head of the CD Provincial Group, told the ACN that the process is currently in a stage of evaluation and inclusion in the territory, where there is a significant number of patients with a mild and moderate diagnosis of this pathology.
She added that a multidisciplinary team made up of neurologists, neuropsychologists and psychiatrists, among other specialties, will participate in the study which will be carried out by the Center for Mental Hygiene, the Provincial Group of CD and in the country it is led by the Center for Molecular Immunology.
According Rodríguez Feria, the evaluation consultations will take place at the Mental Hygiene Center of the city of Holguín and the Lucía Íñiguez Hospital, with the objective of determining the safety and reliability of this medication, as well as the evaluation and laboratory analysis of the patients.
She explained that patients with decompensate underlying diseases or under treatment protocols used in cognitive impairment pathologies will not be considered for inclusion.
The doctor stated that this multicenter and adaptive phase IV trial with duration of 104 weeks will have the participation od 1,400 people from all over Cuba, and will include a diagnostic test at weeks 52 and 78.
In Holguín, the study with NeuroEPO in people with type II Spinocerebellar Ataxia has begun, with 46 patients included so far, which will contribute to improving the treatment protocols for this condition, after concluding the CT, said Rodríguez Feria.
Alzheimer's is a brain disorder that worsens over time and is characterized by the death of neurons, which causes a gradual deterioration of memory, thinking, behavior and social skills and is diagnosed in approximately 55 million people in the next five years. (Source: ACN)
